Yubo International Biotech Limited (YBGJ)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -1.2 Million USD | 21.88% |
| 2021 | -1.54 Million USD | -116.76% |
| 2020 | -711.79 Thousand USD | -1382.91% |
| 2019 | -48 Thousand USD | 17.24% |
| 2018 | -58 Thousand USD | 61.07% |
| 2017 | -149 Thousand USD | -136.51% |
| 2016 | -63 Thousand USD | -8.62% |
| 2015 | -58 Thousand USD | -5.45% |
| 2014 | -55 Thousand USD | 8.33% |
| 2013 | -60 Thousand USD | -27.66% |
| 2012 | -47 Thousand USD | 41.25% |
| 2011 | -80 Thousand USD | -26.98% |
| 2010 | -63 Thousand USD | 50.78% |
| 2009 | -128 Thousand USD | -80.28% |
| 2008 | -71 Thousand USD | 37.17% |
| 2007 | -113 Thousand USD | -25.56% |
| 2006 | -90 Thousand USD | 99.91% |
| 2005 | -101 Million USD | -47995.24% |
| 2004 | -210 Thousand USD | 93.1% |
| 2003 | -3.04 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -324.53 Thousand USD | -413.61% |
| 2023 Q2 | -367.27 Thousand USD | -13.17% |
| 2022 Q4 | 103.48 Thousand USD | 143.43% |
| 2022 Q3 | -238.27 Thousand USD | 51.52% |
| 2022 FY | -1.2 Million USD | 21.88% |
| 2022 Q1 | -578.93 Thousand USD | -49.13% |
| 2022 Q2 | -491.5 Thousand USD | 15.1% |
| 2021 Q1 | -438.57 Thousand USD | -55.71% |
| 2021 Q2 | -370.08 Thousand USD | 15.62% |
| 2021 Q3 | -346.01 Thousand USD | 6.5% |
| 2021 Q4 | -388.19 Thousand USD | -12.19% |
| 2021 FY | -1.54 Million USD | -116.76% |
| 2020 Q4 | -281.65 Thousand USD | 7.49% |
| 2020 FY | -711.79 Thousand USD | -1382.91% |
| 2020 Q3 | -304.46 Thousand USD | -849.02% |
| 2020 Q2 | -32.08 Thousand USD | 77.23% |
| 2020 Q1 | -140.9 Thousand USD | -1661.28% |
| 2019 FY | -48 Thousand USD | 17.24% |
| 2019 Q4 | -8000.00 USD | 0.0% |
| 2019 Q1 | -8000.00 USD | -14.29% |
| 2019 Q2 | - USD | 100.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | -7000.00 USD | 41.67% |
| 2018 FY | -58 Thousand USD | 61.07% |
| 2018 Q3 | -12 Thousand USD | 0.0% |
| 2018 Q1 | 8000.00 USD | 136.36% |
| 2018 Q2 | - USD | -100.0% |
| 2017 Q2 | - USD | 100.0% |
| 2017 Q3 | -22 Thousand USD | 0.0% |
| 2017 FY | -149 Thousand USD | -136.51% |
| 2017 Q1 | -96 Thousand USD | 0.0% |
| 2017 Q4 | -22 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | -13 Thousand USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | -63 Thousand USD | -8.62% |
| 2015 Q1 | -11 Thousand USD | 35.29% |
| 2015 FY | -58 Thousand USD | -5.45% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | -14 Thousand USD | 0.0% |
| 2014 FY | -55 Thousand USD | 8.33% |
| 2014 Q4 | -17 Thousand USD | -21.43% |
| 2014 Q3 | -14 Thousand USD | 0.0% |
| 2013 Q1 | -14 Thousand USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | -60 Thousand USD | -27.66% |
| 2012 FY | -47 Thousand USD | 41.25% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | -9000.00 USD | 30.77% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | -80 Thousand USD | -26.98% |
| 2011 Q1 | -11 Thousand USD | 15.38% |
| 2011 Q4 | -13 Thousand USD | 0.0% |
| 2010 Q4 | -13 Thousand USD | 66.67% |
| 2010 Q1 | -20 Thousand USD | -42.86% |
| 2010 FY | -63 Thousand USD | 50.78% |
| 2010 Q3 | -39 Thousand USD | 0.0% |
| 2009 Q1 | -10 Thousand USD | 0.0% |
| 2009 Q4 | -14 Thousand USD | 0.0% |
| 2009 FY | -128 Thousand USD | -80.28% |
| 2008 FY | -71 Thousand USD | 37.17% |
| 2008 Q1 | 79 Thousand USD | 0.0% |
| 2007 Q1 | -4000.00 USD | 0.0% |
| 2007 FY | -113 Thousand USD | -25.56% |
| 2006 Q1 | 65 Thousand USD | 0.0% |
| 2006 FY | -90 Thousand USD | 99.91% |
| 2005 Q1 | -101.86 Million USD | 0.0% |
| 2005 FY | -101 Million USD | -47995.24% |
| 2004 FY | -210 Thousand USD | 93.1% |
| 2004 Q1 | 16 Thousand USD | 0.0% |
| 2003 FY | -3.04 Million USD | 0.0% |
| 2003 Q1 | -79 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | 203.522% |
| Ansell Limited | 129.3 Million USD | 100.932% |
| Ansell Limited | 129.3 Million USD | 100.932% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | 31.13 Million USD | 103.871% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -1.59 Million USD | 24.471% |
| Psykey, Inc. | -797.5 Thousand USD | -51.124% |
| ConvaTec Group Plc | 262.7 Million USD | 100.459% |
| ConvaTec Group Plc | 262.7 Million USD | 100.459% |
| Encision Inc. | -640.78 Thousand USD | -88.086% |
| Golden Valley Development, Inc | -141.81 Thousand USD | -749.886% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | -996.355% |
| Innovative MedTech Inc. | -4.27 Million USD | 71.802% |
| LifePoint, Inc. | -7.49 Million USD | 83.92% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 81.401% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | 465.219% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Remedent, Inc. | -122.89 Thousand USD | -880.733% |
| Reflect Scientific, Inc. | -467.27 Thousand USD | -157.924% |
| SmileDirectClub, Inc. | -241.15 Million USD | 99.5% |
| Sector 10, Inc. | -39.84 Thousand USD | -2924.854% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | 100.377% |
| SheerVision, Inc. | 155.72 Thousand USD | 873.938% |
| United Health Products, Inc. | -2.42 Million USD | 50.332% |
| Vasamed, Inc. | 4.74 Million USD | 125.414% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 47.465% |